WaveMan
WaveMan · Company
BHVN · Biohaven Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

BHVN Biohaven (BHVN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001935979
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
161
13F, latest reported quarter

Biohaven insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Biohaven Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Clark George C.
VP, Chief Accounting Officer
BUY
2025-11-18 SECtraded 2025-11-17
17,000
$144.8K
+61.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 10, 2022.
  • The trade is 85.0% of the 20,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 161 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, Chief Accounting Officer Clark George C. bought about $144.8K of BHVN on Nov 17, 2025; 3 other insiders bought within 30 days and 161 funds added in the latest 13F quarter.
Bailey Gregory
Director
BUY
2025-11-17 SECtraded 2025-11-13
400,000
$3.0M
+61.8%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Sep 24, 2024.
  • +9.4% median (+28.4% mean) 90-day return after 7 previous buys.
  • The trade is 19.8% of the 2,020,071 shares held after it.
  • 3 other insiders bought within 30 days.
  • 161 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bailey Gregory bought about $3.0M of BHVN on Nov 13, 2025, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 161 funds added in the latest 13F quarter.
CHILDS JOHN W
Director
BUY
2025-11-17 SECtraded 2025-11-13
3,333,333
$25.0M
+61.8%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Mar 4, 2025.
  • +10.2% median (+14.9% mean) 90-day return after 13 previous buys.
  • The trade is 59.0% of the 5,653,904 shares held after it.
  • 3 other insiders bought within 30 days.
  • 161 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CHILDS JOHN W bought about $25.0M of BHVN on Nov 13, 2025, the largest insider purchase at the company since 2022; 3 other insiders bought within 30 days and 161 funds added in the latest 13F quarter.
Coric Vlad
Chief Executive Officer
BUY
2025-11-17 SECtraded 2025-11-13
333,333
$2.5M
+61.8%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Oct 2, 2024.
  • +12.1% median (+16.6% mean) 90-day return after 7 previous buys.
  • The trade is 45.0% of the 740,546 shares held after it.
  • 3 other insiders bought within 30 days.
  • 161 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Coric Vlad bought about $2.5M of BHVN on Nov 13, 2025, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 161 funds added in the latest 13F quarter.
CHILDS JOHN W
Director
BUY
2026-03-09 SECtraded 2025-03-04
28,400
$864.2K
+48.9%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 buys), the last on Dec 30, 2024.
  • +13.3% median (+20.3% mean) 90-day return after 12 previous buys.
  • The trade is 1.2% of the 2,323,971 shares held after it.
  • No other insider bought within 30 days.
  • 161 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CHILDS JOHN W bought about $864.2K of BHVN on Mar 4, 2025; 161 funds added in the latest 13F quarter.
82 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 77 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
161 funds bought in last quarter
more than 84% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
16.3% of the float short (float per yahoo 2026-10-26) · 6.4 days to cover · settled 2026-09-30
more than 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BHVN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-6.2%12M
-52%-31%-10%+11%2025-102025-122026-022026-042026-062026-082026-10 2025-11-13 · CHILDS JOHN W bought $25.0M2025-11-13 · Bailey Gregory bought $3.0M2025-11-13 · Coric Vlad bought $2.5M2025-11-17 · Clark George C. bought $144.8K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BHVN: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
13,210,585 sh
$196.6M
MONTANOVA CAPITAL, LLC
10,286,937 sh
$153.1M
STIFEL FINANCIAL CORP
9,941,165 sh
$147.9M
Jupiter Topco LLC
8,584,675 sh
$127.9M
Woodline Partners LP
7,660,280 sh
$114.0M

Congress trades in BHVN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BHVN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BHVN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
PROFUND VP BIOTECHNOLOGY
$250.1K position · as of 2026-06-30
0.5%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$488.0K position · as of 2026-07-31
0.4%
Direxion Daily S&P Biotech Bull 3X Shares
$1.7M position · as of 2026-07-31
0.4%
Nuveen Life Small Cap Equity Fund
$255.6K position · as of 2026-06-30
0.3%
Nuveen Quant Small Cap Equity Fund
$11.2M position · as of 2026-07-31
0.3%
Inspire Small/Mid Cap ETF
$712.2K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Dr. Vlad Coric
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.5M
-$3.9M
$4.4M
+66%
+52%
2024
$10.5M
$9.8M
$3.9M
+434%
+13%
2023
$6.8M
$22.2M
$2.6M
+511%
+12%
2022
$6.0M
$10.0M
$1.9M
+98%
+4%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 161 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BHVN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$511.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-799.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-127.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-154.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-22.2%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$745.4M-$885.1M-$436.1M-$567.9M
Net income-$738.8M-$846.4M-$408.2M-$570.3M
EPS (diluted)-6.86-9.28-5.73-12.75
Operating cash flow-$609.4M-$582.5M-$331.7M-$297.7M
Cash$230.0M$99.1M$248.4M$204.9M
SEC XBRL, fiscal years, as known on 2026-10-28

BHVN Stock Sonar score 3/7 axes

Find similar shapesCompare

BHVN ranks highest on institutional and government (63rd percentile) and risk and compliance (22nd), and lowest on profitability (13th), among Pharma & Biotech peers.

Profitability
13
Inputs
  • Return on equity-799.5% · 5 pct, sector of 545
  • Return on assets-127.4% · 19 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-154.6% · 15 pct, sector of 576
Institutional and government
63
Inputs
  • Funds adding, latest quarter161 · 84 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$200K · 41 pct, sector of 133
Risk and compliance
22
Inputs
  • Short interest, % of float+16.3% · 22 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies